Titre : Antagonistes du récepteur de type 1 de l'angiotensine-II

Antagonistes du récepteur de type 1 de l'angiotensine-II : Questions médicales fréquentes

Termes MeSH sélectionnés :

Early Detection of Cancer
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Antagonistes du récepteur de type 1 de l'angiotensine-II : Questions médicales les plus fréquentes", "headline": "Antagonistes du récepteur de type 1 de l'angiotensine-II : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Antagonistes du récepteur de type 1 de l'angiotensine-II : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-21", "dateModified": "2025-04-15", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Antagonistes du récepteur de type 1 de l'angiotensine-II" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Antagonistes des récepteurs aux angiotensines", "url": "https://questionsmedicales.fr/mesh/D057911", "about": { "@type": "MedicalCondition", "name": "Antagonistes des récepteurs aux angiotensines", "code": { "@type": "MedicalCode", "code": "D057911", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.162" } } }, "about": { "@type": "MedicalCondition", "name": "Antagonistes du récepteur de type 1 de l'angiotensine-II", "alternateName": "Angiotensin II Type 1 Receptor Blockers", "code": { "@type": "MedicalCode", "code": "D047228", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "None None", "url": "https://questionsmedicales.fr/author/None%20None", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Tadashi Namisaki", "url": "https://questionsmedicales.fr/author/Tadashi%20Namisaki", "affiliation": { "@type": "Organization", "name": "Department of Gastroenterology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan. tadashin@naramed-u.ac.jp." } }, { "@type": "Person", "name": "Kosuke Kaji", "url": "https://questionsmedicales.fr/author/Kosuke%20Kaji", "affiliation": { "@type": "Organization", "name": "Department of Gastroenterology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan." } }, { "@type": "Person", "name": "Naotaka Shimozato", "url": "https://questionsmedicales.fr/author/Naotaka%20Shimozato", "affiliation": { "@type": "Organization", "name": "Department of Gastroenterology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan." } }, { "@type": "Person", "name": "Yukihisa Fujinaga", "url": "https://questionsmedicales.fr/author/Yukihisa%20Fujinaga", "affiliation": { "@type": "Organization", "name": "Department of Gastroenterology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "The impact of race and age on response to neoadjuvant therapy and long-term outcomes in Black and White women with early-stage breast cancer.", "datePublished": "2023-04-29", "url": "https://questionsmedicales.fr/article/37120458", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s10549-023-06943-x" } }, { "@type": "ScholarlyArticle", "name": "Influence of adverse effects of neoadjuvant chemoradiotherapy on the prognosis of patients with early-stage esophageal cancer (cT1b-cT2N0M0) based on the SEER database.", "datePublished": "2023-04-17", "url": "https://questionsmedicales.fr/article/37143768", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fsurg.2023.1131385" } }, { "@type": "ScholarlyArticle", "name": "Modified FOLFIRINOX (mFOLFIRINOX) as neoadjuvant therapy and 'salvage' in patients with high risk locally advanced rectal cancers - tolerance and early outcomes.", "datePublished": "2023-04-07", "url": "https://questionsmedicales.fr/article/38554321", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.4103/jcrt.jcrt_225_22" } }, { "@type": "ScholarlyArticle", "name": "The role of diffusion magnetic resonance imaging in determining tumor aggressiveness during preoperative surgical planning in early-stage endometrial cancer.", "datePublished": "2023-04-04", "url": "https://questionsmedicales.fr/article/37014376", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00117-023-01134-7" } }, { "@type": "ScholarlyArticle", "name": "Survival and prognostic factors of early-stage non-small cell lung cancer in Central and Eastern Europe: A prospective cohort study.", "datePublished": "2023-03-23", "url": "https://questionsmedicales.fr/article/36952375", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/cam4.5791" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Actions chimiques et utilisations", "item": "https://questionsmedicales.fr/mesh/D020164" }, { "@type": "ListItem", "position": 3, "name": "Actions pharmacologiques", "item": "https://questionsmedicales.fr/mesh/D020228" }, { "@type": "ListItem", "position": 4, "name": "Mécanismes moléculaires de l'action pharmacologique", "item": "https://questionsmedicales.fr/mesh/D045504" }, { "@type": "ListItem", "position": 5, "name": "Antagonistes des récepteurs aux angiotensines", "item": "https://questionsmedicales.fr/mesh/D057911" }, { "@type": "ListItem", "position": 6, "name": "Antagonistes du récepteur de type 1 de l'angiotensine-II", "item": "https://questionsmedicales.fr/mesh/D047228" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Antagonistes du récepteur de type 1 de l'angiotensine-II - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Antagonistes du récepteur de type 1 de l'angiotensine-II", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-09", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Antagonistes du récepteur de type 1 de l'angiotensine-II", "description": "Comment diagnostiquer une hypertension ?\nQuels tests pour évaluer l'efficacité des ARA ?\nQuels signes indiquent une insuffisance cardiaque ?\nComment évaluer les effets secondaires des ARA ?\nQuand faire un ECG chez un patient sous ARA ?", "url": "https://questionsmedicales.fr/mesh/D047228?mesh_terms=Early+Detection+of+Cancer&page=998#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Antagonistes du récepteur de type 1 de l'angiotensine-II", "description": "Quels symptômes nécessitent un avis médical urgent ?\nQuels effets secondaires courants des ARA ?\nComment reconnaître une hypotension ?\nQuels symptômes d'une réaction allergique aux ARA ?\nQuels signes d'une hyperkaliémie ?", "url": "https://questionsmedicales.fr/mesh/D047228?mesh_terms=Early+Detection+of+Cancer&page=998#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Antagonistes du récepteur de type 1 de l'angiotensine-II", "description": "Comment prévenir l'hypertension ?\nLe tabagisme influence-t-il l'hypertension ?\nL'alcool affecte-t-il la pression artérielle ?\nComment le stress impacte-t-il la santé cardiaque ?\nQuels aliments éviter pour contrôler la pression ?", "url": "https://questionsmedicales.fr/mesh/D047228?mesh_terms=Early+Detection+of+Cancer&page=998#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Antagonistes du récepteur de type 1 de l'angiotensine-II", "description": "Comment fonctionnent les ARA ?\nQuels sont les ARA les plus prescrits ?\nQuand débuter un traitement par ARA ?\nLes ARA sont-ils sûrs pendant la grossesse ?\nComment ajuster la dose d'ARA ?", "url": "https://questionsmedicales.fr/mesh/D047228?mesh_terms=Early+Detection+of+Cancer&page=998#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Antagonistes du récepteur de type 1 de l'angiotensine-II", "description": "Quelles sont les complications de l'hypertension ?\nComment l'hypertension affecte-t-elle les reins ?\nQuels risques d'AVC liés à l'hypertension ?\nL'hypertension peut-elle causer des problèmes oculaires ?\nQuels effets de l'hypertension sur le cœur ?", "url": "https://questionsmedicales.fr/mesh/D047228?mesh_terms=Early+Detection+of+Cancer&page=998#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Antagonistes du récepteur de type 1 de l'angiotensine-II", "description": "Quels sont les principaux facteurs de risque d'hypertension ?\nLe diabète influence-t-il l'hypertension ?\nL'hérédité joue-t-elle un rôle dans l'hypertension ?\nLe manque d'exercice est-il un facteur de risque ?\nLe stress chronique est-il un facteur de risque ?", "url": "https://questionsmedicales.fr/mesh/D047228?mesh_terms=Early+Detection+of+Cancer&page=998#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une hypertension ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'hypertension est diagnostiquée par des mesures répétées de la pression artérielle." } }, { "@type": "Question", "name": "Quels tests pour évaluer l'efficacité des ARA ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de pression artérielle et des analyses sanguines pour surveiller les électrolytes sont effectués." } }, { "@type": "Question", "name": "Quels signes indiquent une insuffisance cardiaque ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Essoufflement, fatigue, œdèmes et palpitations peuvent indiquer une insuffisance cardiaque." } }, { "@type": "Question", "name": "Comment évaluer les effets secondaires des ARA ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Un suivi régulier des symptômes et des tests sanguins pour les électrolytes est nécessaire." } }, { "@type": "Question", "name": "Quand faire un ECG chez un patient sous ARA ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Un ECG est recommandé si le patient présente des symptômes cardiaques ou des anomalies de pression." } }, { "@type": "Question", "name": "Quels symptômes nécessitent un avis médical urgent ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des douleurs thoraciques, des difficultés respiratoires ou des évanouissements doivent être évalués." } }, { "@type": "Question", "name": "Quels effets secondaires courants des ARA ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires incluent des vertiges, des maux de tête et des troubles gastro-intestinaux." } }, { "@type": "Question", "name": "Comment reconnaître une hypotension ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent des étourdissements, une vision floue et une fatigue excessive." } }, { "@type": "Question", "name": "Quels symptômes d'une réaction allergique aux ARA ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des éruptions cutanées, des démangeaisons ou un gonflement peuvent indiquer une allergie." } }, { "@type": "Question", "name": "Quels signes d'une hyperkaliémie ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des palpitations, une faiblesse musculaire et des picotements peuvent signaler une hyperkaliémie." } }, { "@type": "Question", "name": "Comment prévenir l'hypertension ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée, l'exercice régulier et la gestion du stress aident à prévenir l'hypertension." } }, { "@type": "Question", "name": "Le tabagisme influence-t-il l'hypertension ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme augmente le risque d'hypertension et de maladies cardiovasculaires." } }, { "@type": "Question", "name": "L'alcool affecte-t-il la pression artérielle ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Une consommation excessive d'alcool peut entraîner une augmentation de la pression artérielle." } }, { "@type": "Question", "name": "Comment le stress impacte-t-il la santé cardiaque ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Le stress chronique peut contribuer à l'hypertension et à d'autres problèmes cardiaques." } }, { "@type": "Question", "name": "Quels aliments éviter pour contrôler la pression ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Il est conseillé d'éviter les aliments riches en sodium et en graisses saturées." } }, { "@type": "Question", "name": "Comment fonctionnent les ARA ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les ARA bloquent les récepteurs de l'angiotensine-II, réduisant ainsi la pression artérielle." } }, { "@type": "Question", "name": "Quels sont les ARA les plus prescrits ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Les ARA courants incluent le losartan, le valsartan et l'irbésartan." } }, { "@type": "Question", "name": "Quand débuter un traitement par ARA ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement par ARA est débuté lorsque d'autres antihypertenseurs sont inefficaces ou mal tolérés." } }, { "@type": "Question", "name": "Les ARA sont-ils sûrs pendant la grossesse ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les ARA sont généralement contre-indiqués pendant la grossesse en raison de risques pour le fœtus." } }, { "@type": "Question", "name": "Comment ajuster la dose d'ARA ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "La dose est ajustée en fonction de la réponse du patient et des effets secondaires observés." } }, { "@type": "Question", "name": "Quelles sont les complications de l'hypertension ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent les maladies cardiaques, les AVC et les lésions rénales." } }, { "@type": "Question", "name": "Comment l'hypertension affecte-t-elle les reins ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "L'hypertension peut endommager les vaisseaux sanguins des reins, entraînant une insuffisance rénale." } }, { "@type": "Question", "name": "Quels risques d'AVC liés à l'hypertension ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "L'hypertension augmente le risque d'accident vasculaire cérébral ischémique et hémorragique." } }, { "@type": "Question", "name": "L'hypertension peut-elle causer des problèmes oculaires ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut entraîner des lésions rétiniennes et des problèmes de vision." } }, { "@type": "Question", "name": "Quels effets de l'hypertension sur le cœur ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut provoquer une hypertrophie du cœur, des arythmies et une insuffisance cardiaque." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque d'hypertension ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'âge, l'obésité, le tabagisme et une alimentation riche en sodium." } }, { "@type": "Question", "name": "Le diabète influence-t-il l'hypertension ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le diabète augmente le risque d'hypertension et de complications cardiovasculaires." } }, { "@type": "Question", "name": "L'hérédité joue-t-elle un rôle dans l'hypertension ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux d'hypertension augmentent le risque individuel." } }, { "@type": "Question", "name": "Le manque d'exercice est-il un facteur de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sédentaire contribue à l'augmentation de la pression artérielle." } }, { "@type": "Question", "name": "Le stress chronique est-il un facteur de risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut contribuer à l'hypertension et à d'autres problèmes de santé." } } ] } ] }

Sources (10000 au total)

The impact of race and age on response to neoadjuvant therapy and long-term outcomes in Black and White women with early-stage breast cancer.

There are a paucity of data and a pressing need to evaluate response to neoadjuvant chemotherapy (NACT) and determine long-term outcomes in young Black women with early-stage breast cancer (EBC).... We analyzed data from 2196 Black and White women with EBC treated at the University of Chicago over the last 2 decades. Patients were divided into groups based on race and age at diagnosis: Black wome... Young Black women had the highest risk of recurrence, which was 22% higher than young White women (p = 0.434) and 76% higher than older Black women (p = 0.008). These age/racial differences in recurre... Black women with EBC had significantly worse outcomes compared to White women in our cohort study. There is an urgent need to understand the disparities in outcomes between Black and White breast canc...

Influence of adverse effects of neoadjuvant chemoradiotherapy on the prognosis of patients with early-stage esophageal cancer (cT1b-cT2N0M0) based on the SEER database.

To analyze the prognostic impact of neoadjuvant chemoradiotherapy (NCRT) on early-stage (cT1b-cT2N0M0) esophageal cancer (ESCA) and construct a prognostic nomogram for these patients.... We extracted the clinical data about patients diagnosed with early-stage esophageal cancer from the 2004-2015 period of the Surveillance, Epidemiology, and End Results (SEER) database. We applied the ... Among patients who met the inclusion criteria, patients in the NCRT plus esophagectomy (ES) group had a poorer prognosis for overall survival (OS) and esophageal cancer-specific survival (ECSS) than p... Patients with early-stage ESCA (cT1b-cT2) did not benefit from NCRT, and we established a prognostic nomogram to provide clinical decision aid for the treatment of patients with early-stage ESCA....

Modified FOLFIRINOX (mFOLFIRINOX) as neoadjuvant therapy and 'salvage' in patients with high risk locally advanced rectal cancers - tolerance and early outcomes.

There is limited data with regard to the use of modified 5-fluoroural-leucovorin-irinotecan-oxaliplatin (mFOLFIRINOX) in terms of tolerance and enabling total mesorectal excision (TME) of locally adva... Patients with LARC from January 2018 to December 2020 receiving mFOLFIRINOX post NACTRT/SCRT to facilitate TME were evaluated. The primary endpoint was assessment of grade 3 and grade 4 treatment rela... Forty-seven patients were evaluated with a median age of 33 years (Range:18-59), 45% T4b status, 96% radiological circumferential margin (CRM) involved (79% CRM positive post NACTRT/SCRT), 43% extramu... Locally advanced rectal cancers with high-risk characteristics are a niche group of cancers with less-than-optimal outcomes post standard neoadjuvant strategies. mFOLFIRINOX appears to be well tolerat...

The role of diffusion magnetic resonance imaging in determining tumor aggressiveness during preoperative surgical planning in early-stage endometrial cancer.

The present study aimed to evaluate the relationship between tumor volume and apparent diffusion coefficient (ADC) in preoperative magnetic resonance imaging and deep myometrial invasion, tumor grade,... The study included 73 patients diagnosed with early-stage endometrial cancer based on histopathological examination between May 2014 and July 2019. Receiver operating characteristic (ROC) curve analys... The areas under the ROC curves (AUCs) of ADC and tumor volume in predicting LVI, DMI, and high tumor grade were significantly greater than those for superficial myometrial invasion and low-grade tumor... In the absence of pathological pelvic lymph nodes in early-stage endometrial cancer, tumor volume in DWI sequences determines the active tumor load and tumor aggressiveness. Furthermore, a low ADC ind...

Survival and prognostic factors of early-stage non-small cell lung cancer in Central and Eastern Europe: A prospective cohort study.

Although early diagnosis and surgical resection of the tumor have been shown to be the most important predictors of lung cancer survival, long-term survival for surgically-resected early-stage lung ca... In this prospective study we aimed to investigate the survival and prognostic factors of surgically-resected early-stage non-small cell lung cancer (NSCLC) in Central and Eastern Europe.... We recruited 2052 patients with stage I-IIIA NSCLC from 9 centers in Russia, Poland, Serbia, Czech Republic, and Romania, between 2007-2016 and followed them annually through 2020.... During follow-up, there were 1121 deaths (including 730 cancer-specific deaths). Median survival time was 4.9 years, and the 5-year overall survival was 49.5%. In the multivariable model, mortality wa... This study shows that the 5-year survival rate of surgically-resected stage I-IIIA NSCLC is still around 50% in Central and Eastern Europe. In addition to non-modifiable prognostic factors, lifetime p...

Immune checkpoints expression patterns in early-stage triple-negative breast cancer predict prognosis and remodel the tumor immune microenvironment.

Currently, targeting immune checkpoint molecules holds great promise for triple-negative breast cancer (TNBC). However, the expression landscape of immune checkpoint genes (ICGs) in TNBC remains large... Herein, we systematically investigated the ICGs expression patterns in 422 TNBC samples. We evaluated the ICGs molecular typing based on the ICGs expression profile and explored the associations betwe... Two ICGs clusters and two ICGs-related gene clusters were determined, which were involved in different survival outcomes, biological roles and infiltration levels of immune cells. We established a qua... Collectively, dissecting the ICGs expression patterns not only provides a new insight into TNBC subtypes but also deepens the understanding of ICGs in the tumor immune microenvironment....

Meta-analysis of laparoscopic radical hysterectomy, excluding robotic assisted versus open radical hysterectomy for early stage cervical cancer.

Recent evidence has shown an increase in recurrence and a decrease in overall survival in patients treated with laparoscopic radical hysterectomy (LRH) and robotic assisted radical hysterectomy (RRH) ...

Initial Experience With Trans-anal Minimally Invasive Surgery (TAMIS) for Rectal Polyps and Early Colorectal Cancers at Cumberland Infirmary, Carlisle.

Bowel cancer is the fourth most common type of cancer in the United Kingdom in 2019. Total mesorectal excision is the standard procedure for the removal of rectal tumors, however, it comes with seriou... During a five-year period, 42 patients underwent TAMIS at Cumberland Infirmary. The primary indication for TAMIS was distal rectal lesions, large rectal polyps up to 120 mm, and early rectal cancer (T... Our findings suggest that TAMIS produces positive results. The size of the lesions removed, and the effect of an early learning curve are reflected in the rate of specimen fragmentation and polyp recu...